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Brown adipose tissue (BAT) non-shivering thermogenesis impacts energy homeostasis
in rodents and humans. Mitochondrial uncoupling protein 1 in brown fat cells produces
heat by dissipating the energy generated by fatty acid and glucose oxidation. In addi-
tion to thermogenesis and despite its small relative size, sympathetically activated BAT
constitutes an important glucose, fatty acid, and triacylglycerol-clearing organ, and such
function could potentially be used to alleviate dyslipidemias, hyperglycemia, and insulin
resistance.To date, chronic sympathetic innervation and peroxisome proliferator-activated
receptor (PPAR) γ activation are the only recognized inducers of BAT recruitment. Here,
we review the major differences between these two BAT inducers in the regulation of
lipolysis, fatty acid oxidation, lipid uptake and triacylglycerol synthesis, glucose uptake, and
de novo lipogenesis. Whereas BAT recruitment through sympathetic drive translates into
functionalthermogenicactivity,PPARγ-mediatedrecruitmentisassociatedwithareduction
in sympathetic activity leading to increased lipid storage in brown adipocytes.The promis-
ing therapeutic role of BAT in the treatment of hypertriglyceridemic and hyperglycemic
conditions is also discussed.
Keywords: rosiglitazone, PPARγ, brown adipose tissue, sympathetic nervous system, glucose metabolism, lipid
metabolism, obesity
INTRODUCTION
Brown adipose tissue (BAT) plays an important role in rodent
whole body energy homeostasis due to its extreme ability under
demand to dissipate energy as heat (Cannon and Nedergaard,
2004). This process, known as non-shivering thermogenesis, is
positively regulated through norepinephrine (NE) release by the
sympathetic nerves that densely innervate BAT. Upon sympa-
thetic activation, NE interacts with β3 adrenergic receptors lead-
ing to lipase-mediated triacylglycerol (TAG) hydrolysis. Whereas
lipolysis-derived glycerol is recycled back to TAG by glycerokinase
(GyK;Festucciaetal.,2003a),lipolysis-derivedfattyacids(FA)are
directed to the mitochondria where they either undergo oxida-
tion or allosterically activate uncoupling protein (UCP) 1. Active
UCP1 dissipates the proton gradient across the inner mitochon-
drial membrane, thus leading to heat production at the expense
of ATP synthesis. FA derived from intracellular TAG hydrolysis
are the only activators of UCP1 and mitochondrial uncoupling
as evidenced by defective thermogenesis in mice lacking lipoly-
tic adipose triglyceride lipase (ATGL; Zimmermann et al., 2004).
Therefore,maintenance of intracellular TAG stores is essential for
BAT non-shivering thermogenesis as supported by the marked
increase in BAT TAG synthesis in cold-acclimated rats (Cannon
and Nedergaard, 2004; Moura et al., 2005).
In addition to thermogenesis, sympathetic innervation is a
major regulator of brown adipocyte proliferation, differentiation,
andapoptosisimplicatedinBATmaintenanceandfunction(Can-
non and Nedergaard, 2004). Chronic sympathetic activation not
only increases BAT mass by enhancing brown adipocyte prolifer-
ation and differentiation and by reducing apoptosis (Bronnikov
et al.,1999;Lindquist et al.,2000;Cannon and Nedergaard,2004),
but also stimulates mitochondrial biogenesis and the expression
of the thermogenic proteins UCP1 and peroxisome proliferator-
activated receptor (PPAR) coactivator-1 (PGC-1) α (Puigserver
et al., 1998; de Jesus et al., 2001; Silva, 2006) amplifying BAT
capacity to produce heat (Cannon and Nedergaard, 2004).
Chronic sympathetic activation was the only recognized
inducer of BAT recruitment until the discovery that pharmaco-
logical activation of PPARγ also increases BAT mass and UCP1
levels in rodents (Mercer and Trayhurn, 1986; Rothwell et al.,
1987; Thurlby et al., 1987; Sell et al., 2004). PPARγ is a nuclear
receptor highly expressed in BAT that acts as a master transcrip-
tional regulator of brown adipocyte differentiation required for
tissue development, function, and survival (Barak et al., 1999; He
et al., 2003; Imai et al., 2004; Gray et al., 2006; Duan et al., 2007;
Petrovicetal.,2008).Remarkably,however,PPARγ-mediatedBAT
recruitment is associated with a reduction in BAT sympathetic
activity and thyroid status, which seems to prevent the trans-
lation of a high thermogenic capacity (BAT mass and UCP1
content) into increased functional thermogenic activity (Festuc-
cia et al., 2008). Despite being signiﬁcantly reduced, the residual
sympathetic tone remaining under pharmacological PPARγ acti-
vation modulates major components of PPARγ-mediated BAT
recruitment,includingmaximalUCP1expression(Festucciaetal.,
2010).
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Concomitantly with the upregulation of the thermogenic
potential of BAT, PPARγ activation improves its ability to clear
andstorecirculatinglipidsasTAG,whichisassociatedwithimpor-
tant changes in tissue glucose uptake and utilization. In the past
few years we have worked toward elucidating the mechanisms
whereby PPARγ agonism impacts BAT glucose and lipid metab-
olism. In the following sections we discuss the major ﬁndings
of these studies, their integration into current knowledge on the
mechanisms of action of PPARγ ligands, and future directions of
thisresearcharea.Finally,thepromisingtherapeuticroleof BATas
an energy expending tissue for obesity treatment and as a glucose
and lipid-clearing organ in the treatment of hyperglycemic and
hypertriglyceridemic conditions are addressed.
BROWN ADIPOCYTE LIPOLYSIS
Intracellular lipolysis of TAG to FA and glycerol is directly related
to BAT thermogenic function such that no thermogenesis can
be evoked without activation of lipolysis (Cannon and Neder-
gaard, 2004). TAG hydrolysis is catalyzed in a stepwise manner
by ATGL, hormone-sensitive lipase (HSL), and monoacyglycerol
lipase (MGL), which have preferential hydrolytic activity toward
TAG, diacylglycerol, and monoacylglycerol, respectively (Zechner
et al., 2009). BAT lipolysis is activated by NE released by sympa-
thetic nerves. NE, through activation of β3 adrenergic receptors
and associated adenylyl cyclase, raises cAMP that allosterically
interactsandactivatesproteinkinaseA,whichinturnphosphory-
lates HSL, thereby inducing its translocation to lipid droplets and
increasing its hydrolytic activity.
Peroxisome proliferator-activated receptor γ activation by the
agonist rosiglitazone is associated with an upregulation of BAT
lipolytic machinery due to increased expression of ATGL and its
partner CGI-58 and MGL (Festuccia et al., 2010). Similar to the
upregulation of thermogenic genes, such higher lipase levels are
nottranslatedintohigherfunctionallipolyticratesduetotheinhi-
bitionbyrosiglitazoneofBATsympatheticactivity(Festucciaetal.,
2008). In addition,the release of lipolysis-derived FA from BAT is
counteracted by their intracellular recycling and re-esteriﬁcation
back to TAG,a process that strongly depends upon the generation
of glycerol-3-phosphate (G3P), which is markedly stimulated by
rosiglitazone, as discussed below (Festuccia et al.,2009b).
BROWN ADIPOCYTE FATTY ACID OXIDATION AND
MITOCHONDRIAL BIOGENESIS
Brown adipose tissue has a marked ability to oxidize FA and
glucose as a consequence of high tissue mitochondrial num-
ber and oxidative enzymes content. Such high oxidative capac-
ity is translated into high rates of oxygen consumption, making
BAT the major body oxygen-consuming organ in situations of
active non-shivering thermogenesis (Cannon and Nedergaard,
2004). Lipolysis-derived FA are the preferred substrates oxidized
in BAT,providing most of the energy converted to heat by UCP1-
mediated mitochondrial uncoupling (Cannon and Nedergaard,
2004). Acutely,sympathetic activation upregulates BAT FA oxida-
tionbyincreasinglipolysisandintracellularFAavailability,andby
enhancingcarnitinepalmitoyltransferase(CPT)1activityandFA
entry into the mitochondria (Cannon and Nedergaard, 2004).
Chronically, sympathetic activation upregulates BAT oxidative
capacity by increasing mitochondrial number, an effect medi-
ated by PGC-1α, an adrenergically modulated coregulator of
nuclear receptor function implicated in mitochondrial biogene-
sis (Puigserver et al., 1998). In contrast to sympathetic activa-
tion, PPARγ activation in vivo is not associated with changes in
BAT mitochondrial number and PGC-1α expression (Festuccia
et al., 2010). In brown adipocytes in vitro, rosiglitazone does not
affect PGC-1α expression but increases mitochondrial number
and CPT1 content, such effects being translated into higher oxy-
genconsumptiononlyinthepresenceofNE(Petrovicetal.,2008).
Altogether, these ﬁndings indicate a major role of the sympa-
thetic nervous system to enhance brown adipocyte mitochondrial
function,such action being potentiated by PPARγ activation.
BROWN ADIPOCYTE LIPID UPTAKE AND TRIACYLGLYCEROL
SYNTHESIS
Circulating chylomicron- and very-low-density lipoprotein
(VLDL)-bound TAG are the major source of FA incorporated
into BAT, a process catalyzed by the endothelium-bound enzyme
lipoprotein lipase (LPL), which hydrolyzes circulating TAG to FA
and monoacylglycerol for BAT uptake. BAT is a major plasma
lipid-clearing organ in rodents and therefore a strong modula-
torof triglyceridemia(Festucciaetal.,2009b;Laplanteetal.,2009;
Barteltetal.,2011).Coldexposure,forexample,markedlyactivates
BAT lipid clearance and LPL activity, thus inducing hypotriglyc-
eridemia despite increased liver VLDL–TAG secretion (Mantha
and Deshaies, 1998; Moura et al., 2005; Bartelt et al., 2011). In
addition, BAT lipid uptake in rodents exposed to cold is favored
byanincreaseinthemembraneFAtransporterFAT/CD36(Bartelt
et al.,2011).
Similar to cold exposure, pharmacological PPARγ activation
in rodents markedly increases BAT TAG clearance and LPL activ-
ity, such effects contributing to the hypotriglyceridemic action of
PPARγagonists(Festucciaetal.,2009b;Laplanteetal.,2009).Most
of the FA taken up by brown adipocytes are directed toward TAG
synthesis,aprocessstronglydependentuponG3Pavailability(dis-
cussed below) and the stepwise enzymatic acylation of its carbon
backbone. Initial G3P acylation to lysophosphatidic acid is cat-
alyzed by glycerol-3-phosphate acyltransferase (GPAT; Figure 1).
Lysophosphatidic acid is then acylated to form phosphatidic acid,
which is dephosphorylated to diacylglycerol by phosphatidic acid




and DGAT isoforms, rosiglitazone speciﬁcally increases mRNA
levelsofGPAT3andDGAT1,respectively,bothlocatedintheendo-
plasmic reticulum. GPAT3 and DGAT1 expression is markedly
upregulated by PPARγ activation in 3T3-L1 adipocyte (Cao et al.,
2006;Yenetal.,2008)andinBATsuggestingdirecttranscriptional
regulation, a hypothesis that remains to be tested. Surprisingly,
lipin levels and PAP activity are not affected by rosiglitazone in
BAT (Festuccia et al., 2009b), in contrast with the marked stimu-
lation of lipin-1 levels in rat white adipose tissue (WAT; Festuccia
and Deshaies, 2009; Festuccia et al., 2009a), and that of lipin-1
expression by pioglitazone in WAT of insulin-resistant humans
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(Yao-Borengasser et al., 2006). Noteworthy, PAP speciﬁc activ-
ity (relative to protein) is 5 to 15-fold higher in BAT than in
WAT under basal conditions (Festuccia et al., 2009a); activation
of such abundant lipin-1 in BAT may therefore sufﬁce to accom-
modate the elevated TAG synthetic ﬂux brought by rosiglitazone
without the need to increase lipin expression, as is the case in
WAT.
BROWN ADIPOCYTE GLUCOSE UPTAKE AND
INTRACELLULAR METABOLISM
In BAT, glucose is used not only for G3P synthesis (Figure 1),
the carbon backbone for FA esteriﬁcation, and TAG synthesis,
and that of FA through de novo lipogenesis, but also for energy
generation that supports FA esteriﬁcation to TAG and other
adipocyte functions. Signiﬁcant amounts of glucose in BAT are
also stored as glycogen and converted to lactate by anaerobic
glycolysis (Cannon and Nedergaard, 2004). BAT displays very
high rates of glucose uptake per unit weight, such that even
though BAT makes up only a small fraction of rodent body
weight,it can constitute a signiﬁcant glucose-clearing organ espe-
cially under sympathetic activation (Cannon and Nedergaard,
2004). Such high rates of BAT glucose uptake in humans as
estimated in vivo by positron emission tomography are close
to those seen in cancer, making BAT a confounding factor for
tumor diagnosis. BAT sympathetic activation markedly increases
glucose uptake by activating the glucose transporter (GLUT)
1(Cannon and Nedergaard, 2004). In contrast to sympathetic
activation, however, BAT rates of glucose uptake and GLUT4
mRNA levels are markedly reduced by rosiglitazone. This con-
trasts with the well-established PPARγ effects on glucose uptake
by subcutaneous WAT, skeletal muscle and heart (Zierath et al.,
1998) and excludes a likely contribution of BAT to glucose clear-
ance and the in vivo insulin-sensitizing effect of rosiglitazone in
rodents.
How rosiglitazone reduces BAT glucose uptake is unknown.
It does not seem, however, to involve a direct rosiglitazone effect
on BAT as evidenced by the modest increase in glucose uptake
andunchangedGLUT4mRNAlevelsinisolatedbrownadipocytes
treated with rosiglitazone (Hernandez et al., 2003). Sympathetic
innervation, through NE regulation of GLUT1 content and func-
tionalactivation(Dallneretal.,2006),andinsulin,throughstimu-
lationof GLUT4expressionandtranslocation(Terueletal.,1996),
are the major positive regulators of BAT glucose uptake (Can-
non and Nedergaard, 2004). It is, therefore, reasonable to suggest
that the reduction in both BAT sympathetic drive and plasma
insulinlevelsinducedbyrosiglitazone(Festucciaetal.,2008)might
contribute to reduced BAT glucose uptake.
Likely due to the reduced glucose ﬂux per brown adipocyte,
an important consequence of rosiglitazone treatment is a reduc-
tion in BAT glycogen content, its synthesis from glucose and the
mRNA levels of UDP-linked glucose pyrophosphorylase (UDPG–
PPL), which generates UDP-linked glucose for glycogen syn-
thesis. BAT stores signiﬁcant amounts of glycogen that seem
to be an important source of glucose during non-shivering
thermogenesis as evidenced by the enhanced glycogen utiliza-
tion in BAT of rats exposed to cold (Farkas et al., 1999; Jakus
et al., 2008). During non-shivering thermogenesis, signiﬁcant
FIGURE 1 | Modulation of brown adipose tissue glucose and lipid
metabolism by cold exposure (A) and PPARγ activation (B). Enzymes in
red and pathways with thick arrows are activated in response to
corresponding stimulus. Abbreviations: AGPAT, acylglycerol-
3-phosphate-O-acyltransferase; ATGL, adipose triglyceride lipase; CD36,
fatty acid translocase; DGAT, diacylglycerol acyltransferase; GPAT, glycerol
3-phosphate acyltransferase; GyK, glycerokinase; HSL, hormone-sensitive
lipase; LPL, lipoprotein lipase; MGL, monoacyglycerol lipase; PAP1,
phosphatidic acid phosphatase 1; PKA, protein kinase A; UCP1, uncoupling
protein 1.
amounts of glucose are converted to lactate by anaerobic gly-
colysis, producing ATP that might be important in compen-
sating for reduced energy production due to mitochondrial
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uncoupling (Cannon and Nedergaard, 2004). In addition, glu-
cose seems to play a major role in replenishing citric acid cycle
intermediates (anaplerosis; Owen et al., 2002), which is very
important for keeping elevated levels of FA oxidation (Can-
non and Nedergaard, 2004). Thus the reduction in BAT glucose
uptake and glycogen content induced by rosiglitazone might have
some deleterious consequences in terms of BAT thermogenic
activity.
BROWN ADIPOCYTE G3P GENERATION
TAG synthesis depends on the intracellular levels of G3P. Because
adequatelevelsof TAGforlipolysisandFAproductionaredirectly
related to BAT thermogenic function, the generation of G3P is
maintained under strict control.
The enhanced BAT FA storage induced by PPARγ activation
is associated with a marked increase in TAG-glycerol synthe-
sis estimated with the 3H2O technique, suggesting an increase
in G3P generation by short glycolysis and glyceroneogenesis
(Festuccia et al., 2009b). Indeed, glucose incorporation into
TAG-glycerol in vitro and phosphoenolpyruvate carboxykinase
(PEPCK) activity, a key glyceroneogenesis enzyme, are signiﬁ-
cantly increased by rosiglitazone (Festuccia et al.,2009b). Rosigli-
tazone also increases BAT GyK activity, which generates G3P
by direct phosphorylation of glycerol taken up from the cir-
culation or recycled from TAG hydrolysis. Remarkably, rosigli-
tazone upregulates GyK even under reduced BAT sympathetic
drive (Festuccia et al., 2008), a major positive regulator of BAT
GyK (Kawashita et al., 2002; Festuccia et al., 2003a). Acclima-
tion to cold and now PPARγ agonism are to date the sole known
situations in which all three possible sources of G3P are concomi-
tantly stimulated in BAT (Festuccia et al., 2003a,b; Moura et al.,
2005). Both these situations have in common a marked increase
in BAT LPL activity and FA ﬂux, which further illustrates the
importance of PPARγ in controlling FA esteriﬁcation and TAG
synthesis.
BAT DE NOVO FATTY ACID SYNTHESIS
Along with TAG generation, BAT de novo synthesis of FA is
activated in thermogenic conditions such as cold exposure and
sympathetic stimulation of BAT (Minokoshi et al., 1988;Yu et al.,
2002; Moura et al., 2005). Increased de novo lipogenesis can be
considered as an attempt to maintain TAG levels for subsequent
hydrolysis and thermogenesis activation. Rosiglitazone-mediated
PPARγ activation, however, is not associated with changes in the
rates of BAT de novo FA synthesis as estimated in vivo by the
3H2O technique. This strongly suggests that most of the FA used






tion toward the potential implication of this tissue in metabolic
homeostasis. Despite its small contribution to whole body weight
(∼2% in rodents), BAT has the unique and extraordinary ability
on demand to release energy from FA and glucose oxidation as
heat by non-shivering thermogenesis. During maximal activation
in rodents, BAT is the most oxygen-consuming organ of the
body,producingaconsiderableamountof heatthroughmarkedly
enhanced FA and glucose oxidation (Cannon and Nedergaard,
2004). Thus BAT can potentially constitute a signiﬁcant glucose,
FA, and TAG-clearing organ especially under sympathetic activa-
tion,with possible implications in the treatment of dyslipidemias,
hyperglycemia, and insulin resistance. In this regard, pharma-
cological PPARγ activation emerged as an interesting approach
to recruit BAT alternatively to sympathetic activation (Festuc-
cia et al., 2008; Petrovic et al., 2008). PPARγ agonists markedly
increase rodent BAT mass and its ability to take up and store FA
as TAG. In rodents, BAT signiﬁcantly contributes to the marked
hypolipidemic effects (hypotriglyceridemia and reduced plasma
non-esteriﬁedFA)of PPARγagonists(Laplanteetal.,2007,2009).
The marked ability of BAT to synthesize TAG under PPARγ acti-
vation is related to enhanced generation of G3P and GPAT and
DGATactivities.Anequivalentactivationof BATTAGsynthesisis
only seen during cold exposure (Moura et al., 2005), the sole dif-
ference being that, under this condition of increased sympathetic
activity,newlysynthesizedTAGisrapidlyhydrolyzedtosupplyFA
for thermogenesis, whereas under PPARγ agonism TAG is stored
in BAT, probably as a consequence of reduced tissue sympathetic
drive. In contrast to lipids, however, BAT glucose uptake does not
directlycontributetotheimprovementinsystemicglucosehome-
ostasisinducedbyrosiglitazone.Infact,glucoseuptakeperbrown
adipocyte is reduced by rosiglitazone,in striking contrast with the
effects of the agonist in WAT and muscle.
InviewoftheadverseconsequencesofpharmacologicalPPARγ
activation such as ﬂuid retention, weight gain, congestive heart
failure (Nesto et al., 2003; Lago et al., 2007; Singh et al., 2007),
and osteopenia (Kahn et al., 2008) that currently limit the clini-
cal use of PPARγ agonists as insulin sensitizers, progress is being
made toward the development of selective PPARγ modulators
(SPPARMs). The main goal is to develop SPPARMs that maintain
the beneﬁcial effects of PPARγ activation on insulin sensitivity
and BAT recruitment without the complications linked with full
PPARγ activation.
It is clear, however, that full PPARγ activation is not an efﬁ-
cient strategy to increase BAT thermogenesis and glucose uptake
without the concomitant activation of tissue sympathetic activ-
ity.An ideal SPPARM would recruit BAT without interfering with
basal sympathetic activity, thus enabling functional thermogenic
activity. Efﬁcient PPARγ activation could represent an attractive
strategy to augment BAT thermogenic capacity and sensitivity to
sympatheticstimulation,thusreducingthedosageof β-adrenergic
agonists needed to functionally turn on thermogenesis. Further
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